Low desire from menopause has multiple drivers — hormonal, GSM, mood, sleep. Treatment matches root cause.
Hypoactive sexual desire disorder (HSDD) in menopause is multifactorial. Estrogen loss, painful intercourse from GSM, low testosterone, sleep deprivation, and mood changes all contribute.
Common in peri + postmenopause. Often coexists with other symptoms. Effective treatment requires identifying the dominant driver.
All options below are real published treatments. Evidence-level reflects current clinical guidelines (NAMS / ACOG / Endocrine Society). Cost ranges are starting price estimates from $US public sources.
Monthly cost
$30-$120
Side effects
minimal
If painful intercourse is a driver, fixing dyspareunia often restores desire indirectly.
Providers offering this: midi health, alloy womens health
Monthly cost
$60-$200
Side effects
acne, hirsutism (mild), voice changes (rare at proper dose)
No FDA-approved testosterone formulation for women, but global menopause societies endorse off-label transdermal use in postmenopausal HSDD. Effect modest but real.
Contraindications: Hormone-sensitive cancer history, pregnancy
Providers offering this: alloy womens health, midi health
Monthly cost
$400-$900
Side effects
dizziness, somnolence, hypotension
Daily oral. FDA-approved only for premenopausal women with HSDD. Modest effect; requires abstaining from alcohol.
Monthly cost
$300-$1000 (per injection)
Side effects
nausea, flushing, transient hypertension
On-demand subcutaneous injection 45 min before activity. FDA-approved for premenopausal HSDD only. Limited adoption due to cost + nausea.
Endorsed by global societies for postmenopausal HSDD using transdermal preparations at physiologic doses (≤300 mcg/day). Long-term safety data still emerging — most studies to 2 years suggest safety profile with monitoring.
Last verified 2026-06-01. Treatment guidelines update — confirm with your clinician.